Novel cutaneous eruptions in the setting of programmed cell death protein 1 inhibitor therapy

• Rohan Mital, BS,
• Alexander M. Cartron, MD,
• John C. Trinidad, MD, MPH,
• Natalie Spaccarelli, MD,
• I-sanna Gibbons-Fideler, MD,
• Benjamin H. Kaffenberger, MD, MS,
• Catherine G. Chung, MD

Affiliations

Rohan Mital, BS

Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio

Alexander M. Cartron, MD

Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland

John C. Trinidad, MD, MPH

Department of Dermatology, Massachusetts General Hospital, Cambridge, Massachusetts

Natalie Spaccarelli, MD

Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio

I-sanna Gibbons-Fideler, MD

Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio

Benjamin H. Kaffenberger, MD, MS

Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio

Catherine G. Chung, MD

Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio; Correspondence to: Catherine G. Chung, MD, 2050 Kenny Rd MMT 930, Columbus, OH 43221.